SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Propanc Biopharma Publishes Data on PRP and Chemotherapy-Resistant Cells

Propanc says peer-reviewed research found PRP activity against chemotherapy-resistant pancreatic cancer cells. The company says a Phase 1b first-in-human study is planned.

PPCB

Related stories